Comment in

• The response of NINDS to recommendations from the working group's 2012 review of the Program.

  Ranganathan R. Ranganathan R. Epilepsia. 2012 Oct;53(10):1839-40. doi: 10.1111/j.1528-1167.2012.03668.x. Epilepsia. 2012. PMID: 23030262 No abstract available.
• Addressing the need for new therapies for epilepsy.

  Porter RJ. Porter RJ. Epilepsia. 2012 Oct;53(10):1840-1. doi: 10.1111/j.1528-1167.2012.03670.x. Epilepsia. 2012. PMID: 23030263 No abstract available.
• Seizing the moment for the future: the U.S. Anticonvulsant Screening Project.

  Löscher W, Schmidt D. Löscher W, et al. Epilepsia. 2012 Oct;53(10):1841-2. doi: 10.1111/j.1528-1167.2012.03647.x. Epilepsia. 2012. PMID: 23030264 No abstract available.
• The value of blind screening in the Anticonvulsant Screening Program.

  French J. French J. Epilepsia. 2012 Oct;53(10):1842-3. doi: 10.1111/j.1528-1167.2012.03683.x. Epilepsia. 2012. PMID: 23030265 No abstract available.
• Commentary on Anticonvulsant Screening Program update: children are not little adults.

  Shinnar S, Glauser T. Shinnar S, et al. Epilepsia. 2012 Oct;53(10):1843-4. doi: 10.1111/j.1528-1167.2012.03684.x. Epilepsia. 2012. PMID: 23030266 No abstract available.
• Comments on the working group's 2012 review of the Program.

  Bialer M. Bialer M. Epilepsia. 2012 Oct;53(10):1844-6. doi: 10.1111/j.1528-1167.2012.03682.x. Epilepsia. 2012. PMID: 23030267 No abstract available.